Table 1 Preclinical cancer models used in this study.

From: HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

Model type

Model

Features

Comments

Xenograft lymphoma

Raji B-lymphoma

Human lymphoma xenograft growth in NOD immune-deficient mice. No PD1 targeting can be assessed, while CD47 targeting can be assessed pharmacologically

Cell-derived xenograft

Karpas-299 T-lymphoma

Humanized syngeneic lymphoma (HuGEMM)

huCD47-A20 B-lymphoma syngeneic model

Human PD1, PD-L1, CD47 and SIRPα were knocked-in to immune-competent mice, so both PD1/CD47 targeting can be assessed pharmacologically

Cell-derived homograft

DLBCL PDXs

LY2345, 6701, 12,966, 12,962, 2266, 2264

Similar to other xenografts above, where PD1 targeting cannot be assessed while CD47 targeting can be assessed. Have similar molecular pathology and similar heterogeneity as in patients

A cohort of PDXs can be modeled in clinical trial style trial

Back to article page